Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression

Tumor Biology

Volumn 29, Issue 2, 2008, Pages 63-75

  Paliouras, Miltiadis ^a,b   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Androgen receptor; Breast cancer; Chemical inhibitors, hormone dependent expression; Gene expression; Intracellular signaling pathways; Kallikreins; Steroid hormones; Transcription factors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANDROGEN; KALLIKREIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN; PROTEIN KLK 10; PROTEIN KLK 11; PROTEIN KLK 13; PROTEIN KLK 14; RAS PROTEIN; STEROID; WORTMANNIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 47949084580     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135686     Document Type: Article

References (48)

1. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, Diamandis EP: Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-9041.
2. Magklara A, Grass L, Diamandis EP: Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 2000;59:263-270.
3. Paliouras M, Diamandis EP: Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res Treat 2007;102:7-18.
4. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis EP: Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-3965.
5. Paliouras M, Borgono C, Diamandis EP: Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79.
6. Borgono CA, Michael IP, Diamandis EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-280.
7. Lee DK, Chang C: Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 2003;88:4043-4054.
8. Zhu Z, Becklin RR, Desiderio DM, Dalton JT: Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem Biophys Res Commun 2001;284:836-844.
9. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y: Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-319.
10. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A: Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 1995;5:97-125.
11. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J: Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996;271:6379-6388.
12. Culig Z: Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22:179-184.
13. Rochette-Egly C: Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal 2003;15:355-366.
14. Edwards J, Bartlett JM: The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005;95:1327-1335.
15. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-1989.
16. Uzgare AR, Kaplan PJ, Greenberg NM: Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003;55:128-139.
17. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603.
18. Majumder PK, Sellers WR: Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-7474.
19. Mulholland DJ, Dedhar S, Wu H, Nelson CC: PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006;25:329-337.
20. Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M: The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003;31:169-183.
21. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004;15:1510-1516.
22. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO: The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004;204:93-100.
23. Sharma M, Chuang WW, Sun Z: Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclearβ-catenin accumulation. J Biol Chem 2002;277:30935-30941.
24. Lin HK, Yeh S, Kang HY, Chang C: Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001;98:7200-7205.
25. Chen CD, Sawyers CL: NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862-2870.
26. Sadar MD, Hussain M, Bruchovsky N: Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999;6:487-502.
27. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002;50:222-235.
28. She QB, Solit D, Basso A, Moasser MM: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003;9:4340-4346.
29. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-279.
30. Lee JT Jr, Steelman LS, McCubrey JA: Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004;64:8397-8404.
31. Shaw JL, Diamandis EP: Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53:1423-1432.
32. Luo LY, Grass L, Diamandis EP: Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin Chim Acta 2003;337:115-126.
33. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B: Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002;61:953-963.
34. Shin M, Yan C, Boyd D: An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 2002;1589:311-316.
35. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-233.
36. Jaleel M, Shenoy AR, Visweswariah SS: Tyrphostins are inhibitors of guanylyl and adenylyl cyclases. Biochemistry 2004;43:8247-8255.
37. Conde S, Perez DI, Martinez A, Perez C, Moreno FJ: Thienyl and phenyl α-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3β) from a library of compound searching. J Med Chem 2003;46:4631-4633.
38. Yin X, Giap C, Lazo JS, Prochownik EV: Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003;22:6151-6159.
39. Grad JM, Dai JL, Wu S, Burnstein KL: Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 1999;13:1896-1911.
40. Morin PJ: β-Catenin signaling and cancer. Bioessays 1999;21:1021-1030.
41. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP: Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997;82:777-780.
42. Zarghami N, Grass L, Diamandis EP: Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 1997;75:579-588.
43. Liao DJ, Dickson RB: Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002;80:175-189.
44. Liao DJ, Dickson RB: Steroid hormone-growth factor interactions in proliferative controls of the mammary gland and breast cancer: a rapidly evolving perspective. J Steroid Biochem Mol Biol 2002;80:135-136.
45. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
46. Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
47. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K: Function of the c-Myc oncogenic transcription factor. Exp Cell Res 1999;253:63-77.
48. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-238.